Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification | Alzheimer's Research & Therapy | Full Text

Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification | Alzheimer's Research & Therapy | Full Text

Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification

Cerebrospinal fluid biomarker profiles characterized by decreased amyloid-beta peptide levels and increased total and phosphorylated tau levels at threonine 181 (pT181) are currently used to discriminate betwe...

Authors:Nicolas R. Barthélemy, Randall J. Bateman, Christophe Hirtz, Philippe Marin, François Becher, Chihiro Sato, Audrey Gabelle and Sylvain Lehmann

Citation:Alzheimer's Research & Therapy 2020 12:26

Content type:Research

Published on: 17 March 2020

• ViewFull Text
 
• ViewPDF